Evaluación del perfil de eficacia y seguridad de vildagliptina en vida real de pacientes chilenos con diabetes mellitus tipo 2 / Safety and efficacy of Vildagliptin in real life Chilean diabetic patients
Rev. méd. Chile
;
143(1): 63-68, ene. 2015. graf, tab
Artículo
en Español
| LILACS
| ID: lil-742552
ABSTRACT
Background:
Vildagliptin is a dipeptidyl peptidase IV inhibitor (DPP4i). Its efficacy and safety of DPP4i in Chilean real life type 2 diabetic (T2D) patients is not well known.Aim:
To assess the safety profile and effectiveness of 12 weeks of treatment with Vildagliptin for glycemic control in T2D Chilean patients with a poor glycemic control. Patients andMethods:
Retrospective assessment of the effects of Vildagliptin treatment during 12 weeks in 103 T2D patients aged 29 to 92 years (47% males). The main outcomes were changes in glycosylated hemoglobin and the occurrence of adverse effects.Results:
After 12 weeks of Vildagliptin use, glycosylated hemoglobin decreased from 8.3 ± 1.4 to 7.2 ± 1.1% (p < 0.01). Fasting plasma glucose and the number of hypoglycemic events also decreased significantly. No significant weight change was observed. The treatment had good compliance, tolerance and patient satisfaction.Conclusions:
Vildagliptin treatment reduced glycosylated hemoglobin by 1.1% and was well tolerated in this group of diabetic patients.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Saccharomyces cerevisiae
/
Telomerasa
/
Proteínas de Saccharomyces cerevisiae
País/Región como asunto:
America del Sur
/
Chile
Idioma:
Español
Revista:
Rev. méd. Chile
Asunto de la revista:
Medicina
Año:
2015
Tipo del documento:
Artículo
País de afiliación:
Chile
Institución/País de afiliación:
Hospital del Salvador/CL
Similares
MEDLINE
...
LILACS
LIS